|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
|
31839677 |
2020 |
|
Craniosynostosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with CRS showed significant increases in the expression of ctla4 and jak1 in sinonasal tissue and blood (p < 0.05), whereas the gene expression of hla-dqa1, hla-dqb1, and dusp4 was significantly decreased in patients with CRS compared to controls (p < 0.05).
|
30657646 |
2019 |
|
Diabetes
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrated that diabetes and high glucose exposure decreased DUSP4 expression in cultured podocytes and glomeruli.
|
30862678 |
2019 |
|
Diabetes Mellitus
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In this study, we demonstrated that diabetes and high glucose exposure decreased DUSP4 expression in cultured podocytes and glomeruli.
|
30862678 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thus, this study demonstrates that preserving DUSP4 expression could protect against podocyte dysfunction and preserve glomerular function in DN.
|
30862678 |
2019 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
cAMP Response Element Modulator α Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus.
|
31653682 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
cAMP Response Element Modulator α Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus.
|
31653682 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings identify the CREMα/DUSP4 axis as a promising candidate in the search for biomarkers and therapeutic targets in SLE.
|
31653682 |
2019 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
cAMP Response Element Modulator α Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus.
|
31653682 |
2019 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression.
|
31258782 |
2019 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Another group of 10 new HF, TYP and VB instruments were submitted to 20 cycles of torsional straining between 0° and 180° (Experimental Group - EG) and then submitted to fatigue until rupture under the same conditions of the CG.
|
30133671 |
2018 |
|
Leishmaniasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
DUSP4, an inducible protein has a substrate specificity toward ERK1/2, a component of MAP kinase which is enhanced during Leishmania infection.
|
29133249 |
2018 |
|
Leishmaniasis, Visceral
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to find out the host protective role of DUSP4 in macrophages during VL, we silenced DUSP4 prior to infection and the parasite number within macrophage was counted.
|
29133249 |
2018 |
|
Ureteral obstruction
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We found that the expression of MKP2 was up-regulated in the tubular epithelial of unilateral ureter obstruction rats.
|
30322849 |
2018 |
|
MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our study, it has been Leishmania donovani, the causative agent of visceral leishmaniasis (VL) significantly reduced the expression of DUSP4 during infection.
|
29133249 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Nimbolide suppresses non-small cell lung cancer cell invasion and migration via manipulation of DUSP4 expression and ERK1/2 signaling.
|
28554129 |
2017 |
|
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.
|
26941286 |
2016 |
|
Intraepithelial Neoplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.
|
26941286 |
2016 |
|
Invasive Carcinoma
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.
|
26941286 |
2016 |
|
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DUSP4 gene is underexpressed in ER-negative breast cancer and is deleted in approximately 50 % of breast cancers.
|
27393618 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DUSP4 genomic locus is further deleted in up to 13% of aggressive B cell lymphomas, and the lack of DUSP4 is a negative prognostic factor in three independent cohorts of DLBCL patients.
|
25847947 |
2015 |
|
Hashimoto's encephalitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our in vivo data showed that DUSP4 mice were more resistant to the induction of autoimmune encephalitis, while in vitro differentiations revealed enhanced iTreg and reduced Th17 polarization in DUSP4-deficient T cells.
|
26710253 |
2015 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.
|
25847947 |
2015 |
|
IMMUNODEFICIENCY 13
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings identify a premature T-cell senescence in ICL that might be caused by chronic T-cell activation and a consequential DUSP4-dependent dampening of TCR signaling.
|
25733583 |
2015 |
|
Secondary malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients (238 total) with first-line metastatic colorectal cancer (mCRC) were randomized to FOLFOX or FOLFIRI chemotherapy ± cetuximab. qRT-PCR analyses were conducted on tissues from 103 patients at baseline to measure gene expression levels of HER-related genes, including amphiregulin (AREG), betacellulin (BTC), NT5E (CD73), DUSP4, EGF, EGFR, epigen (EPGN), epiregulin (EREG), HBEGF, ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4), PHLDA1, and TGFA.
|
25520391 |
2015 |